Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Biologic therapy.

Duke University Medical Center, Durham, NC, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Durham, NC
Treatments:Chemotherapy, Biologic therapyHospital:Duke University Medical Center
Drugs:Journal:Link
Date:Oct 2011

Description:

Patients:
This phase II study involved 40 glioblastoma patients who had not received prior treatment with bevacizumab. The median patient age was 51 years and 75% were male.

Treatment:
Patients were treated with the chemotherapy drugs carboplatin and irinotecan, as well as the biologic therapy agent bevacizumab.

Toxicities:
One patient died due to treatment-related intestinal perforation. Grade 3-4 blood clots and neutropenia were also reported, as was grade 3 fatigue, infection, and nausea.

Results:
The median overall survival was 8.3 months.

Support:
This study was partially supported by Genentech, makers of bevacizumab.

Correspondence: Dr. David A. Reardon; email: [email protected]



Back